Headliner: Boehringer Ingelheim's Wa'el Hashad
In October, Boehringer Ingelheim (BI) won FDA approval for Pradaxa, a blood thinner that reduces stroke risk in patients with ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.